WO2007148494A1 - テストステロン増加剤 - Google Patents
テストステロン増加剤 Download PDFInfo
- Publication number
- WO2007148494A1 WO2007148494A1 PCT/JP2007/060341 JP2007060341W WO2007148494A1 WO 2007148494 A1 WO2007148494 A1 WO 2007148494A1 JP 2007060341 W JP2007060341 W JP 2007060341W WO 2007148494 A1 WO2007148494 A1 WO 2007148494A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vitamin
- testosterone
- food
- increasing agent
- menaquinone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to a testosterone increasing agent, and more particularly to a composition for increasing endogenous testosterone.
- Testosterone a type of male hormone, is widely involved in muscle building, cognitive function, vascular flexibility, lipid metabolism, sexual function, and the like. Testosterone secretion decreases with age, but the presence of environmental hormones also affects it. Recently, menaquinone-4 has been implicated in testosterone biosynthesis from DNA microarray analysis of sterile vitamin D-deficient rats! / Possibility of scolding was suggested (Non-patent document 1, Non-patent document 2).
- hormone replacement therapy in which a testosterone preparation is injected.
- injections can cause blood testosterone levels to rise sharply, which can cause upsets.
- hormone replacement therapy may be administered slowly with a transdermal patch.
- Patent Document 1 benzil darcosinolate and benzyl isothiocyanate
- Patent Document 2 a mixture of ma force and antlers included in ma force that does not replenish external force test strons, etc.
- Patent Document 3 a substituted pyrazole compound
- Non-Patent Document 1 8th Vitamin K & Bone Study Group, pp 87-89, December 10, 2005, published by Eisai Co., Ltd.
- Non-patent document 2 Shirakawa et al, Biochim. Biophys. Acta Vitamin K deficiency reduces testosterone production in the testis through down-regulation of the Cypl la a chol esterol side chain cleavage enzyme in rats, ARTICLE In Press, Accepted Manuscrip t, Available online 6 June 2006
- Patent Document 1 JP 2005-306754
- Patent Document 2 Special Table 2003-523945
- Patent Document 3 Special Table 2005-504093
- the compound having the testosterone increasing action described above is a crude drug or a chemically synthesized drug. No such substance is currently known where dietary and safe food ingredients or nutrients that increase blood testosterone levels are preferred. In this situation, it would be desirable to provide a safer and more experienced food ingredient that increases the amount of testosterone.
- vitamin K1 or vitamin K2 ingested from food is converted to menaquinone-4 in the body tissue, and in particular, the testis has increased menaquinone-4 concentration.
- the present inventors have found that the intake of vitamin K can increase the amount of blood testosterone, leading to the present invention. That is, the present invention provides a testosterone increasing agent containing vitamin K.
- vitamin K Conventionally known functions of vitamin K are to maintain blood coagulation normally, promote bone formation, suppress bone resorption, prevent arterial calcification and prevent arteriosclerosis, liver disease Is to treat. It is not known at all that vitamin K has an estrogen increasing effect. Non-patent document 1 and non-patent document 2 suggest that vitamin K is involved in the biosynthesis of testosterone, but the increase in testosterone by vitamin K administration was completely foreseen.
- the vitamin K is preferably vitamin K2.
- the vitamin K is menaquinone-4 and Z or menaquinone-7.
- the present invention provides a medicament for preventing, ameliorating, and / or treating a symptom or disease caused by a decrease in testosterone, comprising the testosterone increasing agent.
- the present invention also provides supplements, health foods or functional foods to which the testosterone increasing agent is added.
- the amount of testosterone in the blood can be easily increased by ingesting vitamin K, which is highly safe for the human body. Fat-soluble vitamin K is more likely to accumulate in the body than conventional testosterone preparations, so it lasts longer. Restoring normal levels of testosterone can maintain or improve the functions that testosterone is involved in (muscle strength, sexual function, etc.) or improve symptoms or illnesses such as male climacteric disorder that develops when testosterone decreases . Since the testosterone increasing agent of the present invention is extremely easy to be taken on a daily basis as a functional food or a health food, the prevention of the symptoms and diseases is also contemplated.
- the recommended amount of vitamins that humans need per day is 55 to 80 g (2005, Japanese dietary intake standard), whereas the upper limit of acceptable intake is 30 mg. It is a highly specific substance. Therefore, the testosterone increasing agent of the present invention is conventionally known and is superior in safety to the testosterone increasing agent.
- FIG. 1 Vitamin K analog in rat testis when the MK-4 diet group according to Example 1 of the present invention and the control diet group and the low K diet group as comparative examples were administered to rats. It is a figure comparing the concentrations.
- FIG. 2 is a graph comparing the P450scc mRNA expression levels in the rat of FIG.
- FIG. 3 is a diagram comparing the amount of P450scc protein in the rat of FIG. 1.
- FIG. 4 is a comparison of plasma testosterone concentrations in the rat of FIG.
- FIG. 5 is a graph showing changes in body weight over time when a vitamin K1-added diet group and an MK-4-added diet group according to Example 2 and a control diet group, which is a comparative example, are administered to rats.
- FIG. 6 is a graph showing daily changes in the intake of the rat in FIG. 5.
- FIG. 7 is a graph comparing the testicular vitamin K concentration in the rat of FIG. 5.
- FIG. 8 is a graph showing changes in blood testosterone levels in the rat of FIG. 5.
- FIG. 9 is a graph comparing testosterone concentrations in the testis of the rat in FIG. 5.
- Vitamin K that can be used in the testosterone increasing agent of the present invention includes vitamins K1 to K3.
- Vitamin K1 also called phylloquinone
- Vitamin ⁇ 2 also called menaquinone
- Vitamin 2 is produced by microorganisms and is abundant in dairy products such as natto and cheese.
- Vitamin ⁇ 2 is also produced by bacteria in the intestinal tract.
- Vitamin 2 has homologues of menaquinone-4 ( ⁇ -4) to menaquinone-15 (MK-15) depending on the length of the side chain isoprenoid group attached to the naphthoquinone skeleton. For example, cheese contains ⁇ -6 to ⁇ -9 and natto contains a large amount of ⁇ -7.
- Vitamin ⁇ 3 also called menadione
- Vitamin ⁇ 3 is a synthetic product.
- vitamin K1 extracted from vegetable power and fermented product power using natto bacteria are extracted from the past food experience. More preferably, it is vitamin 2 that can be produced inexpensively and easily.
- the method for producing each vitamin koji is not particularly limited, and commercially available products can be used without limitation. Specifically, fermentation methods using microorganisms, extraction / purification from foods, and chemical synthesis methods can be used.
- Vitamin K1 is blue shiso, sesame seeds, morohaya, parsley, spring chrysanthemum, komatsuna, spinach, three leaves, alfalfa, weeping leaves, chestnut leaves, young barley stalks, young stalks of wheat , Cabbage, broccoli, cauliflower, tomato, vegetable oil (soybean oil, rapeseed oil, sesame oil, peanut oil
- Vitamin K1 can also be obtained synthetically.
- Vitamin K1 is a light yellow oil soluble in fat and stable to heat and unstable to light.
- Vitamin K1 may be acidic.
- Vitamin 2 is, for example, disclosed in JP-A-08-073396, JP-A-11-92414, JP-A-10-295393, It is fermented and produced by microorganisms such as Bacillus natto according to the method described in Kai-2001-136959.
- the content of vitamin K contained in the testosterone increasing agent of the present invention is a force that varies depending on the intake of the yarn and the composition. Usually, 0.0001 to 100% by weight is preferable, and 0.001% to 90% by weight is preferable. More preferably, it is in the range of 0.01 to 70% by weight, more preferably 1 to 50% by weight. When the content of vitamin K is a 0.0001 0/0 or less, Do can ingest the amount necessary to obtain the testosterone increasing effect, in some cases.
- the testosterone-increasing agent of the present invention is a substance known to increase testosterone in addition to the essential ingredient vitamin K, for example, a plant such as mackerel, a crude drug such as a horn of horn One or more of these extracts, benzyl darcosinolate, benzyl isothiocyanate and substituted pyrazole compounds may be added.
- the testosterone increasing agent of the present invention includes, in addition to the essential ingredient vitamin K and appropriate testosterone increasing agent, pharmacologically usable carriers, excipients, auxiliaries, etc. It can be added in a range without inhibition.
- lactose sucrose, fructose, glucose, glucose hydrate, sucrose, purified sucrose, erythritol, xylitol, sorbitol, mannitol, palatinose, reduced palatinose, powdered reduced maltose, starch, Carmellose, dextrin, corn starch, alpha starch, partially alpha starch, potato starch, corn starch, hydroxypropyl starch, amino acids, kaolin, anhydrous key acid, key acid, aluminum keyeate, sodium bicarbonate, calcium phosphate , Calcium dihydrogen phosphate, calcium carbonate, magnesium oxide, aluminum hydroxide, fatty acid or salt thereof, fatty acid monoglyceride and diglyceride, alcohol, vegetable oil, olive oil, soybean oil, corn oil, fatty oil, fat and oil, Carriers or excipients such as viscous paraffin, propylene glycol, ethylene glycol, polyethylene glycol, glycerin;
- the testosterone increasing agent of the present invention is processed into liquids, powders, granules, tablets, capsules, syrups and the like for use as pharmaceuticals, supplements, functional foods or health foods. Since vitamin K is fat-soluble, the form is tablets or capsules. preferable.
- the testosterone increasing agent of the present invention may be added directly to the raw material during the production of general baked goods such as bread, cooked rice, soup, prepared dishes, confectionery, and candy.
- the method of ingestion when the testosterone increasing agent of the present invention is used as a medicine is not particularly limited.
- oral ingestion transdermal administration, infusion, injection (intramuscular, intraperitoneal, subcutaneous or intravenous).
- injection injection (intramuscular, intraperitoneal, subcutaneous or intravenous).
- tablets or capsules are taken orally in that the burden on the patient is small.
- the pharmaceutical dosage of the testosterone increasing agent of the present invention can be determined in consideration of various factors that affect the patient's symptoms, body weight, administration interval, administration method, and other clinical effects.
- the vitamin K intake per day for an adult male is usually 10 g to 100 mg and preferably g to 100 mg. When used for therapeutic purposes, 6 mg to 10 Omg can be used.
- the intake of vitamin K per day for adult men is 10 ⁇ m in consideration of safety. g-30 mg is preferred 50 ⁇ g-6 mg is more preferred.
- the testosterone increasing agent of the present invention may be used as a medicine or functional food to be ingested by animals other than humans such as male livestock animals and pet animals.
- Administration methods include parenteral intake such as injection, and oral intake in the form of functional foods and mixed feed.
- the testosterone increasing agent of the present invention can be expected to be effective as a therapeutic or prophylactic agent for primary or secondary testicular hypofunction or testosterone deficiency due to aging or environmental factors.
- the testosterone increasing agent of the present invention can prevent, ameliorate, and / or treat various diseases caused by a decrease in testosterone, particularly muscle, cognitive function, concentration, motivation, vascular flexibility, lipid metabolism, Prevention, improvement and Z or treatment of decline in sexual function, male function, urination function, etc. can be expected.
- the effect of enhancing the amount of testosterone in the blood by the testosterone increasing agent of the present invention was examined using a normal rat.
- normal rats In normal rats, it absorbs vitamin K made by intestinal bacteria, so vitamin K is not included in the diet, and even if it is not, extreme vitamin K deficiency does not occur, rats are normal living It is a model that can be put on a human body.
- the experimental animals and the breeding environment are as follows.
- mice Normal rats (Wistar / Std, 8 weeks old male)
- Breeding environment Breeding in a breeding room set at 12 hours light and dark with a temperature of 23 ° C, humidity of 50 ⁇ 5%, lighting at 8:00 am and turning off at 8:00 pm.
- the amount of vitamin K1 in the control diet is the concentration of vitamin K1 used in the standard refined diet of AIN93G, and therefore the control diet group contains the amount of vitamin K taken by the normal diet of rats.
- Vitamin K1 or menaquinone-4 (hereinafter also referred to as MK-4) was added to each experimental food so as to have the composition ratio shown in Table 1, and mixed uniformly.
- Table 1 shows the composition of the experimental food used.
- Vitamin B 12 0.25 mg
- Vitamin K is not added to the low-K diet group, 7.5 mg of K1 is added to the control diet group, and 750 mg of MK-4 is added to the MK-4 diet group, and the total amount is 100 g with sucrose. Adjusted to mix vitamins.
- MR Labstock manufactured by Nippon Agricultural Industry Co., Ltd.
- preliminary breeding was performed with free feeding and free drinking for 3 to 5 days.
- Four rats for each experimental diet group were reared in a wire mesh cage. After pre-breeding, the test food was fed and reared for 35 days with free feeding and free drinking. Blood collection and testis extraction were performed.
- Tissue lg was accurately weighed into a brown centrifuge tube with a stopper, 2 ml of 66% IPA solution was added, and homogenized using a Biotron (polytron homogenizer) under ice cooling. At the time of homogenization, the homogenate on the shaft was washed off with 3 ml of 66% IPA and carved into the sample. To this, 1 ml of hexane solution containing 9.96 ng / ml or 996 ng / ml of MK-3 with 5 ml of hexane as an internal standard was added, and the mixture was extracted by shaking for 5 minutes.
- Vitamin Ks in the prepared HPLC measurement sample are of non-fluorescent acid type. Therefore, the samples were separated by HPLC, and vitamins were quantified by the HPLC-reduction fluorescence method, which measures the fluorescence intensity as a fluorescent reduced form by using a platinum catalyst column. Vitamin K was determined relative to the internal standard MK-3.
- the measurement system for vitamin K by HPLC is as follows.
- Fluorescence detector F-1000 (Hitachi, detection wavelength Ex 240nm, Em 430nm) • Recorder: D-2000 (Hitachi)
- HPLC-reduction is performed by measuring the fluorescence intensity of non-fluorescent acid-vitamin vitamin Ks present in a sample as a fluorescent reduced form by using a platinum catalyst column.
- the fluorescence method is used. Therefore, in the state where oxygen is dissolved in the mobile phase, the reduction is adversely affected. Therefore, the moving bed previously removed the dissolved oxygen by applying ultrasonic waves under reduced pressure, and was bubbled with nitrogen gas (200 ml / min or more) from 2 hours before the measurement until the end.
- RNA extraction reagent About 0.1 lg of the testis of each individual was placed in a special tube, and lml of ISOGEN (NIPP ONGENE), an RNA extraction reagent, was added and homogenized using a Polytron homogenizer. The homogenate was transferred to an Eppendorf tube and left at room temperature for 5 minutes. Thereafter, black mouth form 20001 was added and vigorously stirred for 15 seconds using a vortex. After allowing to stand for 2 to 3 minutes, centrifugation (13000 rpm, 4 ° C, 15 minutes) was performed, and only the upper layer separated into three layers was collected. IPA was added at 500 / zl to this, and after gently shaking it up and down, it was left for 10 minutes.
- ISOGEN NIPP ONGENE
- RNA sample was subjected to absorbance measurement (260 nm, 280 nm) and agarose gel electrophoresis (0.7% TA E agarose gel, 150 V, 35 minutes) to test the concentration and purity of RNA.
- RNA obtained from each individual is dissolved in DEPC-dH 0 so that the concentration is 1 g / 1.
- the solution was dispensed into two PCR tubes. One was prepared for RT (-) with no reverse transcriptase added and for confirming the presence or absence of genomic DNA contamination.
- a reverse transcription reaction was performed at 50 ° C, 60 minutes ⁇ 70 ° C, 15 minutes to obtain a cDNA sample.
- a 100-fold diluted cDNA solution prepared by reverse transcription was used as a sample.
- the reaction reagent used was SYBR Premix Ex Taq (Perfect Real Time) (TaKaRa). Add SYBR Premix Ex Taq 25 ⁇ 1, Rox Reference Dye 1 ⁇ 1, forward and reverse primer solutions 1.5 1 each, dH 0 17 1 to sample or standard cDNA 41
- reaction solution was dispensed into Microwell optical 96-well Reaction Plates in a volume of 24 1 in 2 wells and set in the ABI PRISM 7000 Sequence Detection System.
- GAPDH and eukaryotic cell elongation factor 1a1 are used as internal standard genes for gene expression, and the expression level of each gene is expressed as target gene expression level / internal standard gene expression. The amount was calculated and expressed as a relative value with the value of the control food group being 1.
- Anti-P450scc antibody was purchased from Chemicon.
- SDS buffer 100 ⁇ 1 was added to tissue homogenate (200 ⁇ 1) and left in a boiling water bath for 5 minutes to form SDS.
- the membrane was washed with TBS-T ( e ), and blocked with TBS-T (skim milk solution) containing 5% skim milk for 1 hour.
- the primary antibody reaction was performed for 1 hour in skim milk solution containing anti-P450SCC antibody (1/5000).
- the secondary antibody reaction was performed for 1 hour in a skim milk solution containing anti-Rabbit IgG-HRP antibody (1/5000).
- Anti- ⁇ -actin antibody was used as a control.
- ECL TM Western blotting detection reagent manufactured by Amersham
- Luminescent signal for Las-1000 imaging s Images were obtained with ystem (manufactured by FUJIFILM) and quantified with ImageGauge (trademark) image processing software.
- the protein concentration in the tissue homogenate was measured by the Bradford method. Appropriately diluted 20 ⁇ l of the sample solution was placed in an Eppendorf tube, to which 1 ml of 5-fold diluted Bio-Rad protein assay was added and mixed by vortexing. After 5 minutes at room temperature, the absorbance at 595 nm was measured. As standard curve, ushi serum albumin (BSA) was used.
- BSA ushi serum albumin
- Testosterone EIA kit (Cayman cnemical)
- the recovered ether layer was dried under reduced pressure using a centrifugal vacuum concentrator (TAITEC).
- TITEC centrifugal vacuum concentrator
- the obtained concentrate was dissolved in 0.5 ml of EIA buffer attached to the kit, and this was used as a plasma sample.
- Testicular tissue lOOmg was homogenized using Biotron while cooling with ice in 5 ml of phosphate buffered saline. 1 ml of this homogenate was placed in a test tube, 5 ml of jetyl ether was added, and the mixture was vortexed for about 1 minute and centrifuged (3000 rpm, 4 ° C., 5 minutes).
- Figure 1 shows the low K diet group (without vitamin K added), the control diet group (Kl 0.75 mg / kg added diet), and the M K-4 added diet group (MK-4 75 mg / kg added diet).
- the results of analysis of vitamin K 1 (Right) and MK-4 (Left) concentrations in the testis are shown below. In all cases, it was confirmed that testicular vitamin K was changed to MK-4 regardless of the administration form. Force with no significant difference between low K diet group and control diet group MK-4 concentration was significantly increased in MK-4 diet group.
- FIG. 2 shows the mRNA expression level of P450scc, which is a steroid hormone synthesis pathway gene.
- the low K diet group was slightly lower than the control diet group and the MK-4 supplemented diet group
- FIG. 3 shows the amount of P450scc protein. There was no significant change in the control diet group and the low K diet group, but there was a significant increase in the MK-4 supplemented diet group.
- FIG. 4 shows plasma testosterone concentrations. MK-4 supplemented food group compared to control food group As a result, plasma testosterone concentration increased significantly.
- Vitamin K concentration in the control diet contains the necessary amount of vitamin K, which is the amount that can be consumed in daily diets, and a lack of vitamin K rarely reduces blood testosterone. It is not considered.
- blood testosterone was increased by actively taking vitamin K according to the present invention. Therefore, if blood testosterone is reduced for some reason, blood testosterone is increased by taking vitamin K. be able to.
- Example 1 the laboratory animals and the rearing environment are normally 12 hours of HWistar / Std (8-week-old male) at 23 ° C, 50 ⁇ 5% humidity, 8 am on, 8 pm off. The animals were reared in a breeding room set for light and dark cycles.
- Control diet group (vitamin 0.75mg / kg supplemented diet)
- Vitamin K1 added food group (Vitamin Kl 75 mg / kg added food)
- Vitamin K1 was purchased from Wako Pure Chemical Industries, Ltd. Menaquinone-4 was manufactured by Nisshin Faluma. Each experimental diet should have vitamin K1 or MK-
- the breeding period was 35 days, and blood was collected from the tail vein at 18:00 every week. Measurement items include body weight, food intake, testicular vitamin K content, testicular testosterone concentration, and plasma testosterone concentration.
- the analysis method is the same as in Example 1.
- Testicular vitamin K and testosterone data were analyzed using the Tukey method. Two-way analysis of variance (with repetitions) was used to analyze changes in blood testosterone concentration over time. In all cases, a significant difference was P 0.05.
- FIG. 7 shows the results of testicular vitamin K concentration (Right: vitamin Kl, Left: MK-4). In both the vitamin K1 and MK-4 diet groups, testicular MK-4 concentrations increased markedly. It is thought that vitamin K1 was converted to MK-4 in the body.
- FIG. 8 shows changes in blood testosterone levels.
- the blood testosterone level in the vitamin K1-supplemented group was strong at the 4th and 5th weeks with no difference from the control group. In the second and third weeks, it was stronger than the control diet group.
- a two-way analysis of variance analysis was performed throughout, and a significant difference was found at P 0.01. In the MK-4 addition group, a significant difference was observed in the results of two-way analysis of variance (P 0.01) in which the blood testosterone concentration was high between 2 and 5 weeks after administration.
- FIG. 9 shows the testosterone concentration results in the testis.
- the testosterone level also increased.
- vitamin K1 and vitamin K2 were found to increase the amount of testosterone in blood and testis.
- vitamin K2 is administered. Since no changes in body weight or changes in dietary intake were observed, increasing testosterone with vitamin K is a safe method.
- Testosterone enhancer containing vitamin K as an active ingredient.
- Testosterone consisting of a testosterone enhancer containing vitamin K as an active ingredient A drug to prevent, ameliorate, and / or treat symptoms or diseases caused by a decrease in
- vitamin K is vitamin K2.
- symptom and illness are muscle, cognitive function, concentration, motivation, vascular flexibility, lipid metabolism, sexual function, male function or decreased urinary function.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007800233762A CN101472574B (zh) | 2006-06-23 | 2007-05-21 | 睾丸酮增强剂 |
JP2008522346A JP5110478B2 (ja) | 2006-06-23 | 2007-05-21 | テストステロン増加剤 |
US12/305,403 US8686049B2 (en) | 2006-06-23 | 2007-05-21 | Agent for increasing testosterone level |
EP07743775A EP2033634A4 (en) | 2006-06-23 | 2007-05-21 | AGENT FOR INCREASING TESTOSTERONE RATE |
US14/178,409 US20140228447A1 (en) | 2006-06-23 | 2014-02-12 | Agent for increasing testosterone level |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-173455 | 2006-06-23 | ||
JP2006173455 | 2006-06-23 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12305403 A-371-Of-International | 2008-12-18 | ||
US14/178,409 Division US20140228447A1 (en) | 2006-06-23 | 2014-02-12 | Agent for increasing testosterone level |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007148494A1 true WO2007148494A1 (ja) | 2007-12-27 |
Family
ID=38833237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/060341 WO2007148494A1 (ja) | 2006-06-23 | 2007-05-21 | テストステロン増加剤 |
Country Status (7)
Country | Link |
---|---|
US (2) | US8686049B2 (ja) |
EP (1) | EP2033634A4 (ja) |
JP (1) | JP5110478B2 (ja) |
KR (1) | KR20090023562A (ja) |
CN (1) | CN101472574B (ja) |
RU (1) | RU2431475C2 (ja) |
WO (1) | WO2007148494A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140171918A1 (en) * | 2012-12-14 | 2014-06-19 | Bioject, Inc. | Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men |
WO2023170591A2 (en) * | 2022-03-09 | 2023-09-14 | Synergia Life Sciences Pvt Ltd. | Novel menaquinone-n (vitamin-k2-7) supplementation for livestock and poultry |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05155803A (ja) | 1991-11-30 | 1993-06-22 | Honen Corp | 天然ビタミンk濃縮物の製造方法 |
JPH0873396A (ja) | 1994-07-07 | 1996-03-19 | Honen Corp | 天然メナキノン−7高含量脂質 |
JPH10165139A (ja) * | 1996-12-10 | 1998-06-23 | Kumamoto Seifun Kk | 食品用ビタミンk補給組成物の製造方法とビタミンkの抽出方法 |
JPH10295393A (ja) | 1997-04-30 | 1998-11-10 | New Food Kurieeshiyon Gijutsu Kenkyu Kumiai | ビタミンkの製造法 |
JPH1156232A (ja) * | 1997-08-26 | 1999-03-02 | Snow Brand Milk Prod Co Ltd | ビタミンk及びカルシウムを強化した乳及び乳製品 |
JPH1192414A (ja) | 1997-09-25 | 1999-04-06 | New Food Creation Gijutsu Kenkyu Kumiai | ビタミンk2 濃縮物の製造法 |
JPH11127816A (ja) * | 1997-10-27 | 1999-05-18 | Sanei Gen Ffi Inc | ビタミンkを含有する食品 |
JP2001136959A (ja) | 1999-11-17 | 2001-05-22 | Hiroyuki Sumi | 枯草菌菌体および/またはその産生物を含む培養物、これに由来する水溶性ビタミンk誘導体、これらを含む医薬、食品および飼料ならびにこれらの製造方法 |
JP2003063970A (ja) * | 2001-08-27 | 2003-03-05 | Honen Corp | 抗骨粗鬆症組成物 |
JP2003523945A (ja) | 1999-08-31 | 2003-08-12 | バイオティクス、リサーチ、コーポレーション | テストステロン濃度を増強するためのマカおよび枝角 |
JP2003226639A (ja) * | 2002-01-31 | 2003-08-12 | Hisamitsu Pharmaceut Co Inc | 神経成長因子活性増強剤としてのビタミンk類を含む医薬組成物およびその使用 |
JP2005504093A (ja) | 2001-09-27 | 2005-02-10 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | 内因性テストステロンレベルの増加方法 |
JP2005306754A (ja) | 2004-04-19 | 2005-11-04 | Towa Corporation 株式会社 | テストステロン増加組成物、テストステロン増加食品、テストステロン増加皮膚外用およびテストステロン増加薬 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3836242B2 (ja) * | 1998-01-16 | 2006-10-25 | 陽子 竹中 | ビタミンk類及び機能性食品の製造方法並びに機能性食品 |
-
2007
- 2007-05-21 CN CN2007800233762A patent/CN101472574B/zh not_active Expired - Fee Related
- 2007-05-21 US US12/305,403 patent/US8686049B2/en not_active Expired - Fee Related
- 2007-05-21 JP JP2008522346A patent/JP5110478B2/ja active Active
- 2007-05-21 RU RU2008148542/15A patent/RU2431475C2/ru not_active IP Right Cessation
- 2007-05-21 EP EP07743775A patent/EP2033634A4/en not_active Withdrawn
- 2007-05-21 WO PCT/JP2007/060341 patent/WO2007148494A1/ja active Application Filing
- 2007-05-21 KR KR1020087027209A patent/KR20090023562A/ko not_active Application Discontinuation
-
2014
- 2014-02-12 US US14/178,409 patent/US20140228447A1/en not_active Abandoned
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05155803A (ja) | 1991-11-30 | 1993-06-22 | Honen Corp | 天然ビタミンk濃縮物の製造方法 |
JPH0873396A (ja) | 1994-07-07 | 1996-03-19 | Honen Corp | 天然メナキノン−7高含量脂質 |
JPH10165139A (ja) * | 1996-12-10 | 1998-06-23 | Kumamoto Seifun Kk | 食品用ビタミンk補給組成物の製造方法とビタミンkの抽出方法 |
JPH10295393A (ja) | 1997-04-30 | 1998-11-10 | New Food Kurieeshiyon Gijutsu Kenkyu Kumiai | ビタミンkの製造法 |
JPH1156232A (ja) * | 1997-08-26 | 1999-03-02 | Snow Brand Milk Prod Co Ltd | ビタミンk及びカルシウムを強化した乳及び乳製品 |
JPH1192414A (ja) | 1997-09-25 | 1999-04-06 | New Food Creation Gijutsu Kenkyu Kumiai | ビタミンk2 濃縮物の製造法 |
JPH11127816A (ja) * | 1997-10-27 | 1999-05-18 | Sanei Gen Ffi Inc | ビタミンkを含有する食品 |
JP2003523945A (ja) | 1999-08-31 | 2003-08-12 | バイオティクス、リサーチ、コーポレーション | テストステロン濃度を増強するためのマカおよび枝角 |
JP2001136959A (ja) | 1999-11-17 | 2001-05-22 | Hiroyuki Sumi | 枯草菌菌体および/またはその産生物を含む培養物、これに由来する水溶性ビタミンk誘導体、これらを含む医薬、食品および飼料ならびにこれらの製造方法 |
JP2003063970A (ja) * | 2001-08-27 | 2003-03-05 | Honen Corp | 抗骨粗鬆症組成物 |
JP2005504093A (ja) | 2001-09-27 | 2005-02-10 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | 内因性テストステロンレベルの増加方法 |
JP2003226639A (ja) * | 2002-01-31 | 2003-08-12 | Hisamitsu Pharmaceut Co Inc | 神経成長因子活性増強剤としてのビタミンk類を含む医薬組成物およびその使用 |
JP2005306754A (ja) | 2004-04-19 | 2005-11-04 | Towa Corporation 株式会社 | テストステロン増加組成物、テストステロン増加食品、テストステロン増加皮膚外用およびテストステロン増加薬 |
Non-Patent Citations (5)
Title |
---|
"8th Vitamin K and Bone Meeting Records", 10 December 2005, EISAI CO., LTD., pages: 87 - 89 |
KOMAI M. ET AL.: "Recent Topics in the Studies of Laboratory of Nutrition, Tohoku University: Newly Clarified Function of Vitamin K", TOHOKU JOURNAL OF AGRICULTURAL RESEARCH, vol. 57, no. 1-2, November 2006 (2006-11-01), pages 19 - 31, XP003019683 * |
See also references of EP2033634A4 * |
SHIRAKAWA ET AL., BIOCHIM. BIOPHYS. ACTA VITAMIN K, 6 June 2006 (2006-06-06) |
SHIRAKAWA H. ET AL.: "Vitamin K deficiency reduces testosterone production in the testis through down-regulation of the Cyplla a cholesterol side chain cleavage enzyme in rats", BIOCHIMICA ET BIOPHYSICA ACTA, 6 June 2006 (2006-06-06), XP005666480 * |
Also Published As
Publication number | Publication date |
---|---|
RU2008148542A (ru) | 2010-06-20 |
EP2033634A1 (en) | 2009-03-11 |
JP5110478B2 (ja) | 2012-12-26 |
EP2033634A4 (en) | 2010-12-22 |
KR20090023562A (ko) | 2009-03-05 |
JPWO2007148494A1 (ja) | 2009-11-19 |
CN101472574A (zh) | 2009-07-01 |
CN101472574B (zh) | 2011-06-15 |
US8686049B2 (en) | 2014-04-01 |
RU2431475C2 (ru) | 2011-10-20 |
US20090209653A1 (en) | 2009-08-20 |
US20140228447A1 (en) | 2014-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5145035B2 (ja) | β−クリプトキサンチンの使用 | |
KR20140022888A (ko) | 영양 조성물 | |
JP2009173634A (ja) | ポリ−γ−グルタミン酸を含有する脂質吸収阻害剤 | |
WO2017045034A1 (en) | Ubiquinone and ubiquinol compositions, and methods relating thereto | |
KR20160022292A (ko) | 요산치 저하제 | |
WO2005074907A1 (ja) | 遺伝子発現調節剤 | |
WO2009136587A1 (ja) | 抗疲労組成物 | |
EP1964568A1 (en) | Utilization of hypertension/hypercardia-preventing effect of d-allose | |
WO2007148494A1 (ja) | テストステロン増加剤 | |
JP2010222284A (ja) | 血中gip上昇抑制剤 | |
KR20150063006A (ko) | 난각막 성분을 포함한 인슐린 저항성 개선제 및 그것을 이용한 조성물 | |
TW201410238A (zh) | 含有芝麻素類及γ-米糠醇及米胚芽油之組成物 | |
US20210251932A1 (en) | Method Of Treatment Of Obesity | |
JP2010163403A (ja) | イソプラスタン低下剤 | |
JP2022159178A (ja) | 抗老化用組成物 | |
JP2009073749A (ja) | セサミン類とγ−オリザノールとを含有する組成物 | |
TW202239401A (zh) | 正丁基苯酞於促進脂肪褐變、以及預防或治療脂肪肝及相關肝病變之應用 | |
WO2015062167A1 (zh) | Metrnl蛋白在制备降血脂降血糖药物中的应用 | |
JP7430442B2 (ja) | グレリン受容体の活性化剤 | |
JP6417120B2 (ja) | 経口紫外線抵抗性向上剤 | |
KR20140074268A (ko) | 고순도 epa를 함유하는 항비만제 | |
WO2024071138A1 (ja) | ミトコンドリア機能向上用組成物 | |
US20150045433A1 (en) | Methods and compositions for inducing physiological hypertrophy | |
WO2022224776A1 (ja) | 脂質減少促進剤 | |
JP6374682B2 (ja) | 筋萎縮抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780023376.2 Country of ref document: CN |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07743775 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008522346 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007743775 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087027209 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 9770/DELNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008148542 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12305403 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |